Daniel Orlando is the founder of Alcresta. Alcresta has raised $139M in total funding. Latest round: Series A. Based in Newton, United States.
Daniel Orlando is the Chief Executive Officer and a member of the Board of Directors at Alcresta Therapeutics, Inc., a commercial-stage company focused on developing and commercializing novel, enzyme-based products for gastrointestinal disorders and rare diseases. He joined Alcresta in June 2019. Prior to this role, he served as Chief Operating Officer at Vericel Corporation and held executive positions at Takeda and Abbott Laboratories, bringing over 18 years of experience in leading organizations through rapid growth and product launches.
Full founder directory · Investor directory · Company funding database · Fundraising library